IHC: Definition, Uses, and Clinical Overview

IHC Introduction (What it is)

IHC stands for immunohistochemistry, a laboratory method used to study proteins in tissue.
It helps pathologists identify what type of cells are present and what markers they express.
IHC is commonly used on biopsy or surgery specimens when cancer is suspected or confirmed.
The results can support diagnosis and help guide treatment planning.

Why IHC used (Purpose / benefits)

In oncology care, many diseases can look similar under a microscope. IHC helps solve this problem by adding “molecular labels” to tissue sections so specific proteins can be seen and measured in context. Pathologists use these protein patterns to clarify what a tumor is, where it likely started, and how it may behave.

Key purposes and benefits of IHC include:

• Improving diagnostic accuracy: IHC can help distinguish cancer from non-cancer conditions (such as inflammation) and separate different cancer types that may share similar appearance on routine staining.
• Determining tumor lineage and subtype: Many cancers require more than “carcinoma” or “sarcoma” as a label. IHC can support classification (for example, helping separate a lung adenocarcinoma from squamous cell carcinoma, or refining a lymphoma subtype).
• Identifying the likely site of origin: When cancer is found in one place but the primary site is unclear, IHC panels can support a “best-fit” origin based on marker patterns. This is especially relevant in cancers of unknown primary.
• Assessing predictive biomarkers: Some IHC markers correlate with benefit from certain therapies (for example, hormone receptors in breast cancer or other actionable proteins in specific settings). Whether a marker is clinically predictive varies by cancer type and stage.
• Supporting prognosis and risk stratification: In selected cancers, the presence, absence, or level of certain proteins may be associated with a different risk profile. How this is used varies by clinician and case.
• Enabling standardized reporting: Many IHC results are scored using established criteria to help oncology teams make consistent decisions across settings.

IHC is not a treatment by itself. It is a diagnostic and decision-support tool that helps the care team choose the most appropriate management pathway.

Indications (When oncology clinicians use it)

Common situations where IHC is used include:

• A biopsy shows a tumor, and the exact cancer type or subtype needs clarification.
• A tumor’s appearance overlaps with multiple possibilities (a differential diagnosis), and additional markers are needed.
• A patient has metastatic disease, and the likely primary site is uncertain.
• The oncology team needs biomarker status to guide therapy selection (varies by cancer type and stage).
• A lymph node or bone marrow sample suggests a hematologic malignancy, and classification requires immunophenotyping (often alongside flow cytometry and molecular tests).
• A prior diagnosis is being re-reviewed for confirmation, second opinion, or updated classification.
• A recurrence is suspected, and clinicians need to confirm whether it represents recurrent cancer, a new primary, or a non-malignant process.
• A specimen has limited tumor, and the lab must use tissue-sparing strategies to answer key clinical questions.

Contraindications / when it’s NOT ideal

IHC is widely applicable, but it is not always the best or sufficient approach. Situations where IHC may be less suitable include:

• Insufficient or poor-quality tissue: Very small biopsies, crushed tissue, extensive necrosis, or scant tumor cells can limit reliability.
• Suboptimal fixation or processing: Delayed fixation, over-fixation, or certain decalcification methods (often used for bone) can reduce antigen detection and affect interpretation.
• When DNA/RNA-level testing is required: Some clinical questions are better answered by molecular methods (for example, certain gene fusions, mutations, or minimal residual disease assessments), depending on the cancer type.
• High risk of misleading results from artifacts: Background staining, edge effects, or endogenous pigments can complicate interpretation.
• When time is critical and a faster method is appropriate: In some urgent scenarios, another test may be used first, with IHC added later as needed (varies by institution and case).
• When marker expression is known to be non-specific in that context: Some proteins are shared across multiple tumor types; IHC results must be interpreted with morphology and clinical data.

When IHC is not ideal, clinicians and laboratories may rely more heavily on routine histology, cytology, flow cytometry, in situ hybridization, or molecular testing, depending on the question being asked.

How it works (Mechanism / physiology)

IHC works by using antibodies (immune proteins made to recognize a specific target) to detect antigens (proteins or other targets) inside cells or on cell surfaces within a tissue section.

High-level mechanism:

1. Tissue is preserved and sliced: A biopsy or surgical specimen is fixed (commonly in formalin), embedded in paraffin, and cut into thin sections placed on slides.
2. Antibodies bind to targets: A primary antibody is applied to the slide. If the target protein is present, the antibody binds to it.
3. A detection system makes binding visible: A secondary antibody and enzyme or fluorescent label is used to generate a colored reaction (chromogenic IHC) or a fluorescent signal (immunofluorescence), highlighting where the protein is located.
4. A pathologist interprets the pattern: Interpretation considers which cells stain, where staining occurs (nucleus, cytoplasm, membrane), how strong, and how many cells are positive, along with the tumor’s microscopic appearance and clinical context.

Relevant tumor biology and tissue context:

• Cancer is driven by changes in cell growth and regulation. Many of these changes involve protein expression (increased, decreased, or abnormal localization).
• IHC measures protein expression in the architecture of the tissue, helping distinguish tumor cells from surrounding benign cells, immune cells, and stromal tissue.
• Some IHC markers reflect cell of origin (lineage markers), while others reflect pathway activity or therapeutic targets.

Onset/duration/reversibility:

• IHC does not have an “onset” or “duration” in the way a medication does.
• The relevant concept is turnaround time (how long the lab takes to produce results) and stability of the biomarker (whether expression may change over time or after treatment). Biomarker stability varies by cancer type, treatment exposure, and specimen site.

IHC Procedure overview (How it’s applied)

IHC is not a treatment procedure performed on a patient directly. It is a laboratory test performed on tissue that has already been collected. A typical clinical workflow looks like this:

1. Evaluation/exam: A clinician evaluates symptoms, exam findings, and medical history and identifies a need for tissue diagnosis.
2. Imaging/biopsy/labs: Imaging may guide a biopsy, or a surgical procedure may remove tissue. Routine blood tests may be done depending on the situation.
3. Staging (if cancer is confirmed): Imaging and other tests help determine disease extent. Staging systems vary by cancer type.
4. Pathology review (core step for IHC): – The lab processes the specimen and performs routine histology (commonly H&E staining). – If additional clarification is needed, the pathologist orders IHC stains, often as a panel rather than a single marker. – The pathologist integrates IHC results with morphology and clinical information and issues a report.
5. Treatment planning: The oncology team uses the diagnosis, stage, and biomarker information (when relevant) to discuss management options.
6. Intervention/therapy: Treatment may include surgery, radiation therapy, systemic therapy, or combinations, depending on cancer type and stage.
7. Response assessment: Follow-up imaging, exams, and sometimes repeat biopsy may be used to assess response (varies by clinician and case).
8. Follow-up/survivorship: Long-term monitoring focuses on recurrence surveillance, late effects, symptom management, and supportive care needs.

Types / variations

IHC can be tailored to different clinical questions, specimen types, and laboratory platforms. Common types and variations include:

• Diagnostic IHC panels (tumor typing): Panels designed to classify tumors by lineage or differentiation (for example, epithelial vs melanocytic vs lymphoid). Specific marker choices vary by lab and suspected diagnosis.
• Predictive biomarker IHC (therapy selection support): Tests that help determine whether a tumor expresses a target associated with certain treatments. How strongly this guides treatment varies by cancer type and stage and by available therapies.
• Prognostic IHC markers: Markers sometimes used to refine risk estimates. Use depends on guidelines, tumor type, and clinical setting.
• Single-marker vs panel testing: A single stain may answer a focused question, but many cases require multiple stains interpreted together.
• Chromogenic IHC vs immunofluorescence:
• Chromogenic IHC produces a colored stain visible with standard microscopy and is common in surgical pathology.
• Immunofluorescence uses fluorescent labels and is used in selected contexts.
• Manual vs automated IHC platforms: Many labs use automated instruments for standardization and reproducibility, though manual methods are also used.
• Multiplex IHC / spatial profiling approaches: Some settings use multiple markers on the same tissue section to evaluate tumor and immune microenvironment patterns. Availability varies by institution.
• Solid-tumor vs hematologic applications:
• Solid tumors often rely on IHC integrated with histologic subtype and stage.
• Hematologic malignancies may use IHC alongside flow cytometry, cytogenetics, and molecular studies.
• Primary diagnosis vs recurrence/metastasis workup: Marker selection may differ depending on whether the question is initial classification or confirming a metastasis.

Pros and cons

Pros:

• Helps refine or confirm a diagnosis beyond routine microscopy.
• Preserves tissue context, showing which cells express a marker and where in the tumor it appears.
• Can support therapy planning when a marker is clinically relevant (varies by cancer type and stage).
• Often uses existing biopsy tissue without requiring a new procedure.
• Can be standardized with controls and scoring systems in many common applications.
• Useful across many specimen types (biopsies, resections, lymph nodes), depending on tissue quality.

Cons:

• Results depend on tissue handling (fixation, processing) and can be affected by artifacts.
• Some markers are not fully specific; interpretation requires clinical and morphologic correlation.
• Limited tissue can constrain the number of stains and may force prioritization of questions.
• Scoring can have inter-observer variability, especially in borderline or heterogeneous cases.
• Not all clinically important alterations are detectable by protein expression alone; molecular testing may still be needed.
• Tumors can be heterogeneous, meaning different areas may show different staining patterns.

Aftercare & longevity

Because IHC is performed on a specimen rather than administered to a patient, “aftercare” mainly relates to understanding results and ensuring they are used appropriately in the broader care plan.

Practical factors that affect how IHC results influence care over time include:

• Cancer type and stage: The role of biomarkers and the weight given to IHC findings varies by tumor type and how advanced the disease is.
• Tumor biology and heterogeneity: Some tumors show mixed or changing marker expression within the same tumor or between primary and metastatic sites.
• Specimen timing and site: A marker profile from an older specimen may not fully reflect current disease after treatment. Whether repeat testing is useful varies by clinician and case.
• Quality of the tissue sample: Adequate tumor content and good fixation support more reliable interpretation.
• Integration with other tests: IHC is often most informative when combined with morphology, imaging, and other laboratory studies (such as molecular profiling when indicated).
• Follow-up and communication: Clear pathology reporting and clinician-patient discussions help ensure results are understood in context, including limitations and next steps.
• Supportive care and survivorship needs: While IHC itself does not create side effects, the treatment decisions informed by pathology may lead to supportive care needs that evolve over time.

Alternatives / comparisons

IHC is one tool within a broader diagnostic and treatment-planning pathway. Common alternatives and complementary approaches include:

• Routine histology (H&E) alone: Many diagnoses can be made without IHC, especially when morphology is classic. IHC is added when the appearance is ambiguous or when biomarker data is needed.
• Special stains (non-antibody stains): Certain organisms or tissue components may be highlighted with traditional stains; these can complement IHC depending on the question.
• Flow cytometry (especially in hematologic malignancies): Flow cytometry analyzes cells in suspension and can rapidly assess multiple markers. It is often complementary to IHC, which preserves tissue architecture.
• In situ hybridization (ISH) and FISH: These detect DNA or RNA targets in tissue and can be used for gene amplifications, rearrangements, or certain viral associations, depending on cancer type.
• PCR-based testing and next-generation sequencing (NGS): These look for mutations, fusions, and other genomic alterations. Compared with IHC, molecular tests may provide more direct genetic information but may not show spatial context in the same way.
• Cytology (cell samples) with ancillary testing: Fine-needle aspiration and body fluid cytology can be paired with IHC or molecular tests, but cellularity and specimen preparation can be limiting.
• Clinical trials and expanded profiling: In some settings, broader biomarker testing may be pursued to assess eligibility for clinical trials. Whether this is appropriate varies by cancer type, stage, and local availability.
• Observation/active surveillance: This is a management strategy rather than a diagnostic test. In selected low-risk situations, clinicians may monitor rather than immediately treat, but the initial diagnosis often still relies on pathology, sometimes including IHC.

Overall, IHC is often compared with molecular methods: IHC measures protein expression, while many molecular tests measure genetic changes. They can agree, complement each other, or occasionally differ, and differences are interpreted in clinical context.

IHC Common questions (FAQ)

Q: Is IHC the same as a biopsy?
IHC is not a biopsy. A biopsy is the procedure that collects tissue, while IHC is a laboratory test performed on that tissue. If the original sample is adequate, IHC can often be done without another procedure.

Q: Does IHC hurt or require anesthesia?
IHC itself does not involve a procedure on your body, so it does not cause pain and does not require anesthesia. Any discomfort would be related to how the tissue was collected (for example, a needle biopsy or surgery). The type of anesthesia for tissue collection varies by clinician and case.

Q: What does an IHC result actually show?
An IHC report shows whether a specific protein marker is present in tumor cells and often describes the staining pattern and intensity. Some tests are reported as positive/negative, while others use a scoring method. The meaning of a result depends on the cancer type, the marker tested, and the overall pathology findings.

Q: How long does IHC take to come back?
Turnaround time varies by laboratory, the number of stains ordered, and whether additional testing is needed. Some cases require multiple rounds of stains or outside consultation. Your care team can explain what is typical for your setting.

Q: Can IHC be wrong (false positive or false negative)?
Like any lab test, IHC can be affected by technical factors and interpretation challenges. Tissue handling, tumor heterogeneity, and marker non-specificity can contribute to misleading results. Pathologists use controls and correlation with microscopy and clinical information to reduce these risks.

Q: Will IHC tell me my cancer stage?
IHC does not stage cancer by itself. Staging typically depends on tumor size/extent, lymph node involvement, and spread to other sites, assessed through pathology, imaging, and clinical evaluation. IHC can provide biomarker information that complements staging but does not replace it.

Q: Are there side effects from IHC?
There are no direct physical side effects because IHC is performed on tissue in a lab. However, the results may influence treatment choices, and treatments can have side effects. Discussions about treatment effects are typically based on the overall care plan rather than the IHC test alone.

Q: How much does IHC cost?
Costs vary widely by healthcare system, insurance coverage, the number of stains performed, and whether the test is considered standard or specialized. Some patients see separate charges for pathology services and for specific biomarker tests. Your clinic or hospital billing team can explain the expected cost range for your situation.

Q: Will IHC affect my ability to work or do normal activities?
IHC itself does not affect daily activities because it is not performed on your body. Activity limits, if any, relate to the biopsy or surgery used to obtain tissue and to any treatment that follows. Recovery expectations vary by procedure type and individual health factors.

Q: Does IHC have implications for fertility or pregnancy?
IHC does not affect fertility or pregnancy because it is a lab analysis. However, some IHC findings may help determine whether hormone-related pathways are involved in a cancer, which can influence treatment options. Fertility considerations are usually addressed during treatment planning and vary by cancer type and stage.